How should thrombin time (TT) be interpreted?

How to Interpret Thrombin Time (TT)

Thrombin time is primarily a qualitative screening test that is highly sensitive to direct thrombin inhibitors (dabigatran) and unfractionated heparin (UFH), where a normal TT effectively excludes clinically relevant levels of these anticoagulants, but a prolonged TT cannot quantify their concentration and requires further investigation to determine the underlying cause. 1, 2, 1

Primary Clinical Applications

Screening for Anticoagulants in Emergency Settings

When anticoagulant history is unknown, TT should be measured alongside PT/INR, aPTT, and anti-Xa activity to detect or exclude any anticoagulant presence 1. This panel approach is essential because:

• Normal TT rules out clinically relevant dabigatran or UFH levels 2
• Prolonged TT indicates presence but does not distinguish between clinically significant and insignificant levels 2

Specific Anticoagulant Detection

For dabigatran:

• Normal TT excludes clinically relevant levels (>50 ng/mL for serious bleeding, >30 ng/mL for high-risk procedures) 2
• Prolonged TT confirms presence but requires diluted thrombin time or ecarin chromogenic assay for quantification 1, 3
• TT is exquisitely sensitive to dabigatran, making it unsuitable for monitoring therapeutic levels 4

For heparin:

• TT is highly sensitive to UFH 1, 3
• Weakly sensitive to LMWH (except tinzaparin) 1
• Can distinguish heparin contamination when combined with Reptilase time: prolonged TT + normal Reptilase = heparin; both prolonged = other cause 5

Differential Diagnosis of Prolonged TT

When TT is prolonged, systematically consider 6:

1. Anticoagulant inhibition (most common):

   • Exogenous heparin or dabigatran
   • Endogenous heparin-like anticoagulants
   • Rarely: anti-bovine thrombin antibodies

2. Fibrinogen abnormalities:

   • Qualitative: dysfibrinogenemia (congenital or acquired)
   • Quantitative: hypofibrinogenemia or afibrinogenemia

3. Fibrin polymerization defects:

   • Fibrin/fibrinogen degradation products
   • Paraproteins
   • Rarely: acquired anti-fibrinogen antibodies

Critical Interpretation Pitfalls

Do not use TT for:

• Quantifying dabigatran or heparin concentrations—it only confirms presence 2, 4
• Monitoring therapeutic anticoagulation—use specific assays (diluted TT for dabigatran, anti-Xa for heparins) 1
• Assessing factor Xa inhibitors (apixaban, rivaroxaban, edoxaban)—TT is insensitive to these agents 1

Common false positives:

• Heparin contamination from improper blood draw 5
• Sample collection issues affecting fibrinogen 5

Algorithmic Approach to Prolonged TT

1. Confirm anticoagulant exposure history

   • If on dabigatran: normal TT excludes residual drug; prolonged requires quantitative diluted TT 3, 4
   • If heparin suspected: perform Reptilase time to distinguish from other causes 5

2. If no anticoagulant history:

   • Check fibrinogen level (Clauss method preferred) 5
   • If fibrinogen low: quantitative disorder
   • If fibrinogen normal/high: consider dysfibrinogenemia or inhibitors 6

3. For suspected dysfibrinogenemia:

   • Perform TT mixing studies at 1:2,1:4, and 1:5 dilutions with normal plasma 7
   • Complete correction at specific dilution helps guide fibrinogen replacement dosing 7

4. Emergency bleeding scenarios:

   • Normal TT in patient on suspected dabigatran = safe to proceed with urgent intervention 2
   • Prolonged TT with dabigatran = consider idarucizumab (5g IV) for life-threatening bleeding 3, 4

Key Limitations

TT cannot reliably:

• Exclude on-therapy levels of anticoagulants when normal (reagent sensitivity varies) 2
• Quantify the degree of anticoagulation 1
• Detect low molecular weight heparins (except tinzaparin) 1
• Assess vitamin K antagonists or direct factor Xa inhibitors 1

The timing of blood sampling relative to anticoagulant administration is paramount for interpretation—always document when the last dose was taken 8.